Altre lingue Lyra Therapeutics, Inc.

Azioni

LYRA

US55234L1052

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 28/06/2024			Variaz. 5gg	Var. 1 gen.
0,2767 ^USD	+5,93%		+2,41%	-94,72%

21/05	Lyra Therapeutics riduce la forza lavoro per estendere la sua pista di liquidità	MT
21/05	Lyra Therapeutics, Inc. annuncia il licenziamento di John E. Bishop come Chief Technology Officer, con effetto a partire dal 20 giugno 2024 circa	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Lyra Therapeutics Reduces Workforce to Extend Cash Runway	21/05
Lyra Therapeutics, Inc. Announces Termination of John E. Bishop as Chief Technology Officer, Effective on or About June 20, 2024	21/05
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital	21/05
Lyra Therapeutics, Inc. Announces Cost-Cutting Measures to Preserve Capital	21/05
Lyra Therapeutics Phase 3 Trial of LYR-210 Falls Short of Primary Endpoint, Plans to Cut Staff; Shares Drop Pre-Bell	06/05
Lyra Therapeutics Lead Drug Candidate Fails in Phase 3 Study	06/05
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis	06/05
Lyra Therapeutics, Inc. Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis	06/05
Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	30/04
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	30/04
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	26/04
Lyra Therapeutics, Inc. Announces Board Changes	19/04
Lyra Therapeutics Files $300 Million Mixed Shelf Offering	22/03
Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	21/03
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	01/03
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	07/11
Lyra Therapeutics to Participate in Upcoming Investor Conferences	07/11
Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer	16/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Lyra Therapeutics, Inc.

Azioni

LYRA

US55234L1052

Altre lingue

Filtri